

Peter Mollee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6480680/publications.pdf>

Version: 2024-02-01

96
papers

3,001
citations

218677

26
h-index

175258

52
g-index

97
all docs

97
docs citations

97
times ranked

3836
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. <i>Blood Cancer Journal</i> , 2021, 11, 6.	6.2	5
2	Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. , 2021, 42, 11-16.		1
3	The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. <i>Bone Marrow Transplantation</i> , 2021, 56, 2152-2159.	2.4	5
4	The Clinical Impact of Proteomics in Amyloid Typing. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1122-1127.	3.0	9
5	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-eligible patients with myeloma who are treated with bortezomib-based induction. <i>European Journal of Haematology</i> , 2021, 107, 497-499.	2.2	2
6	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	27.0	268
7	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. <i>HemaSphere</i> , 2021, 5, e648.	2.7	3
8	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). <i>Blood</i> , 2021, 138, 2728-2728.	1.4	1
9	PI3K-p110 α contributes to antibody responses by macrophages in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 451-461.	7.2	8
10	Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. <i>Leukemia and Lymphoma</i> , 2020, 61, 2738-2742.	1.3	2
11	A Cost-Effectiveness Analysis of Front-Line Treatment Strategies in Early Stage Follicular Lymphoma. <i>Blood</i> , 2020, 136, 54-55.	1.4	1
12	Management and Outcomes of Testicular Lymphoma in the Rituximab Era at an Australian Tertiary Centre. <i>Blood</i> , 2020, 136, 25-26.	1.4	0
13	The Use of Monocyte Subset Repartitioning By Flow Cytometry for Diagnosis of Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
14	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 36-38.	1.4	0
15	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e415-e424.	0.4	13
16	Amyloidosis in Australia. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 37-39.	0.8	0
17	Pomalidomide – Author Reply. <i>Leukemia and Lymphoma</i> , 2019, 60, 1105-1105.	1.3	0
18	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	9.6	330

#	ARTICLE	IF	CITATIONS
19	Report of the Survey Conducted by RCPAQAP on Current Practice for Paraprotein and Serum Free Light Chain Measurement and Reporting: a Need for Harmonisation. <i>Clinical Biochemist Reviews</i> , 2019, 40, 31-42.	3.3	4
20	Proposed Addendum to 2012 Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand. <i>Clinical Biochemist Reviews</i> , 2019, 40, 23-30.	3.3	3
21	Paraprotein Sample Exchange in Australia and New Zealand - 2018. <i>Clinical Biochemist Reviews</i> , 2019, 40, 43-54.	3.3	3
22	A global call to arms for clinical laboratories – Harmonised quantification and reporting of monoclonal proteins. <i>Clinical Biochemistry</i> , 2018, 51, 4-9.	1.9	19
23	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	1.0	11
24	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-543.	1.6	168
25	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.8	10
26	The Utility of 99m Tc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience. <i>Heart Lung and Circulation</i> , 2017, 26, 1183-1190.	0.4	23
27	Cardiac amyloid imaging with ¹⁸ F-florbetaben positron emission tomography: a pilot study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 162-162.	3.0	15
28	Malabsorption Secondary to Gout-Induced Amyloidosis. <i>ACG Case Reports Journal</i> , 2017, 4, e32.	0.4	5
29	Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 707-718.	2.8	18
30	Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 921-7.	2.3	14
31	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	1.4	37
32	International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial. <i>American Journal of Transplantation</i> , 2015, 15, 1091-1100.	4.7	48
33	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 94-105.	0.8	13
34	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2015, 45, 335-343.	0.8	6
35	Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1774-1779.	0.7	13
36	Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis. <i>Blood</i> , 2015, 126, 1779-1779.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2014, 4, e170-e170.	6.2	80
38	Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. <i>Leukemia and Lymphoma</i> , 2014, 55, 97-104.	1.3	31
39	Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. , 2014, 86, 80-90.		4
40	How to diagnose amyloidosis. <i>Internal Medicine Journal</i> , 2014, 44, 7-17.	0.8	67
41	Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 246-254.	1.1	6
42	Successful Treatment of Iatrogenic Multicentric Castleman's Disease Arising Due to Recrudescence of HHV-8 in a Liver Transplant Patient. <i>American Journal of Transplantation</i> , 2014, 14, 1207-1213.	4.7	8
43	Using HitAlert flow cytometry to detect heparin-induced thrombocytopenia antibodies in a tertiary care hospital. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 365-370.	1.0	16
44	CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5675-5685.	7.0	26
45	Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2303-2310.	2.3	27
46	Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival. <i>Internal Medicine Journal</i> , 2013, 43, 953-954.	0.8	2
47	Diagnosis Of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS) Proteomic Analysis. <i>Blood</i> , 2013, 122, 5295-5295.	1.4	1
48	Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. <i>Blood</i> , 2013, 122, 1780-1780.	1.4	0
49	CD62L Expression Is Associated With Chronic Lymphocytic Leukemia (CLL) Cell Survival In Vitro and Represents a Novel Therapeutic Target In CLL. <i>Blood</i> , 2013, 122, 4136-4136.	1.4	2
50	Serum Levels Of CD178 (Soluble FasL) Predict Treatment Response and Survival In Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2013, 122, 2866-2866.	1.4	0
51	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 242-256.	1.6	71
52	Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. <i>Leukemia and Lymphoma</i> , 2012, 53, 1077-1083.	1.3	16
53	CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. <i>Leukemia and Lymphoma</i> , 2012, 53, 1988-1998.	1.3	62
54	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. <i>Lancet Oncology</i> , The, 2012, 13, 196-206.	10.7	349

#	ARTICLE	IF	CITATIONS
55	Homozygous <i>FCGR3A</i> Δ 158V alleles predispose to late onset neutropenia after CHOP for diffuse large B-cell lymphoma. <i>Internal Medicine Journal</i> , 2012, 42, 1113-1119.	0.8	23
56	Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT. <i>Thrombosis and Haemostasis</i> , 2012, 107, 575-583.	3.4	43
57	WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. <i>Leukemia Research</i> , 2012, 36, 453-458.	0.8	26
58	A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. <i>British Journal of Haematology</i> , 2012, 157, 766-769.	2.5	9
59	Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population. <i>Leukemia and Lymphoma</i> , 2011, 52, 85-91.	1.3	27
60	Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. <i>Internal Medicine Journal</i> , 2011, 41, 408-415.	0.8	1
61	Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. <i>Journal of Hospital Infection</i> , 2011, 78, 26-30.	2.9	121
62	Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. <i>Annals of Hematology</i> , 2011, 90, 359-360.	1.8	6
63	Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. <i>Blood</i> , 2011, 118, 1585-1585.	1.4	1
64	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. <i>American Journal of Blood Research</i> , 2011, 1, 146-59.	0.6	19
65	Myeloablative Allogeneic Stem Cell Transplantation for Non-Hodgkin's Lymphoma. , 2010, , 89-108.		0
66	Borderline High Serum Free Light Chain λ/κ Ratios Are Seen Not Only in Dialysis Patients but Also in Non-Dialysis-Dependent Renal Impairment and Inflammatory States. <i>American Journal of Clinical Pathology</i> , 2009, 132, 309-309.	0.7	15
67	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. <i>Blood</i> , 2009, 114, 100-100.	1.4	6
68	Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. <i>Clinical Biochemist Reviews</i> , 2009, 30, 113-8.	3.3	33
69	Quantitative serum free light chain assay-analytical issues. <i>Clinical Biochemist Reviews</i> , 2009, 30, 131-40.	3.3	66
70	Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. <i>Clinical Biochemist Reviews</i> , 2009, 30, 93-103.	3.3	18
71	A ≥ 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. <i>Leukemia and Lymphoma</i> , 2008, 49, 517-523.	1.3	48
72	Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. <i>Clinica Chimica Acta</i> , 2007, 376, 30-36.	1.1	89

#	ARTICLE	IF	CITATIONS
73	Analytical performance of serum free light-chains assay. <i>Clinica Chimica Acta</i> , 2007, 380, 250-251.	1.1	2
74	Palifermin-induced acanthosis nigricans. <i>Internal Medicine Journal</i> , 2007, 37, 417-418.	0.8	18
75	Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. <i>Internal Medicine Journal</i> , 2007, 37, 456-463.	0.8	26
76	Epstein-Barr virus T-cell immunity despite rituximab. <i>British Journal of Haematology</i> , 2007, 136, 628-632.	2.5	14
77	The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. <i>Hematological Oncology</i> , 2006, 24, 159-163.	1.7	19
78	A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. <i>Hematology</i> , 2006, 11, 25-29.	1.5	19
79	Effects of Hyperlipidemia on Plasma Sodium, Potassium, and Chloride Measurements by an Indirect Ion-Selective Electrode Measuring System. <i>Clinical Chemistry</i> , 2006, 52, 155-156.	3.2	56
80	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 460-464.	7.0	129
81	Serum free light chains for monitoring multiple myeloma. <i>British Journal of Haematology</i> , 2005, 128, 405-406.	2.5	14
82	Stem cell transplantation for mantle cell lymphoma: if, when and how?. <i>Bone Marrow Transplantation</i> , 2005, 36, 655-661.	2.4	11
83	Increased Lipid Concentration Is Associated with Increased Hemolysis. <i>Clinical Chemistry</i> , 2005, 51, 2425-2425.	3.2	32
84	Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?. <i>Leukemia and Lymphoma</i> , 2005, 46, 217-223.	1.3	11
85	The reporting of serum protein electrophoresis to clinicians. <i>Clinica Chimica Acta</i> , 2005, 358, 204-205.	1.1	6
86	Interferon- γ -2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. <i>Annals of Oncology</i> , 2004, 15, 1810-1815.	1.2	6
87	Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2004, 33, 1201-1208.	2.4	16
88	Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.. <i>Blood</i> , 2004, 104, 5213-5213.	1.4	0
89	Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. <i>British Journal of Haematology</i> , 2003, 120, 978-985.	2.5	98
90	Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?. <i>Bone Marrow Transplantation</i> , 2003, 31, 953-960.	2.4	15

#	ARTICLE	IF	CITATIONS
91	Measurement of Immunoglobulin Free Light Chains in Serum: Response. <i>Clinical Chemistry</i> , 2003, 49, 1958-1958.	3.2	2
92	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma*. <i>British Journal of Haematology</i> , 2002, 119, 125-127.	2.5	58
93	Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 30, 273-278.	2.4	27
94	Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. <i>British Journal of Haematology</i> , 2001, 113, 217-223.	2.5	24
95	Single institution outcomes of treatment of severe aplastic anaemia. <i>Internal Medicine Journal</i> , 2001, 31, 337-342.	0.8	3
96	Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. <i>Leukemia Research</i> , 1999, 23, 177-183.	0.8	9